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See Article, pages 1070–1079Although the outcome of acute liver failure (ALF) has improved
due to developments in the general intensive care techniques,
mortality rates without transplantation in patients who fulﬁl
poor prognostic criteria are still in excess of 80%. Besides
N-acetylcysteine, there are no speciﬁc treatment options for
ALF that occurs on the background of acetaminophen (APAP)
toxicity. Also, strategies to limit progression of acute liver injury
in patients who are progressing to ALF remain an unmet need.
Further difﬁculties in the management of patients with ALF are
the lack of biomarkers that may indicate progression of liver fail-
ure early as decision making regarding listing for transplantation
in patients with ALF is challenging. At present, the criteria that
are used to list patients for urgent transplantation lack sensitivity
[1]. Therefore, the paper by Antoine and colleagues [2] in the
present issue of the Journal is welcome as it starts to address
these two areas of unmet need.
The features of APAP-induced hepatotoxicity are apoptosis,
necrosis, and innate immune activation [3]. It is important to
have a clear understanding of the cellular mechanisms that
underlie APAP toxicity as this will not only provide an opportu-
nity to develop biomarkers; the use of these biomarkers will also
allow for risk stratiﬁcation of patients and in doing so, optimise
patient care in those presenting following an APAP overdose. In
order to address this issue, the authors measured full length
keratin-18 (FL-K18) and High Mobility Group Box-1 (HMGB1)
as circulating indicators of necrosis, and caspase-cleaved frag-
ment of keratin-18 (cK18) and hyper-acetylated HMGB1 during
(APAP) toxicity as serum indicators of apoptosis and immune cell
activation, respectively, in patients with APAP-induced acute
liver injury and ALF. Their data suggest that these markers accu-
rately reﬂect severity and pattern of liver injury during its differ-
ent phases and are potentially important biomarkers that may
provide accurate prognostic information.
Keratin-18 (K18) is an intermediate ﬁlament responsible for
maintaining the cytoskeletal structure in the liver and other epi-
thelial cells. K18 accounts for about 5% of the liver’s total protein
content. Hepatocyte apoptotic cell death is associated with the
release of caspase-cleaved K18 (cK18). Intact full length K18 isJournal of Hepatology 20
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E-mail address: r.jalan@ucl.ac.uk (R. Jalan).released from cells undergoing necrosis [4]. There are sandwich
ELISAs available which are able to determine the different forms
of K18. The M30 ELISA measures the cK18 released during apop-
tosis whilst the M65 ELISA detects a common epitope present in
the full-length protein as well as caspase-cleaved fragment and is
believed to measure both apoptosis and necrosis [4]. Craig et al.
recently evaluated the use of cK18 and total K18 to aid prognos-
tication in acute liver injury and following APAP overdose. They
found that although the total K18 (but not cK18) levels were sig-
niﬁcantly higher in the patients with APAP-induced acute liver
injury, it failed to predict survival [5]. This conﬂicts with previous
results from Volkman et al. who suggest that a higher level of
cK18 is associated with spontaneous recovery from ALF [6]. In
addition, an interesting study by Bechmann et al., which utilised
a modiﬁed Model for End-Stage Liver Disease (MELD) score, in
which serum bilirubin was substituted with K18/M65, demon-
strated that the modiﬁed M65-based MELD was signiﬁcantly bet-
ter at predicting prognosis in ALF patients compared with the
current MELD score or Kings College Criteria (KCC) [7].
HMGB1 is a DNA-binding molecule which targets toll-like
receptors and the receptor for advanced glycation end products.
The protein has different functions depending on its cellular loca-
tion. Intracellularly, it is involved in transcription, replication,
and DNA repair. Outside of cells, it functions as an ‘‘alarmin’’ that
can signal danger and traumatic cell death and distress. It is a
trigger for inﬂammation and a stimulus for tissue reconstruction
[8]. However, recent data suggest that HMGB1 on its own is
insufﬁcient to trigger sustained pro-inﬂammatory responses
and must act in conjunction with molecules such as lipopolysac-
charide (LPS) and interleukins to elicit a strong and sustained
pro-inﬂammatory response [8,9]. HMGB1 is released in a hyper-
acetylated form from innate immune cells and in a hypoacetylat-
ed form by necrotic cells [3]. There is a widely used commercially
available ELISA kit which measures HMGB1 concentrations in
biological ﬂuids [10]. Antoine et al. demonstrated in a mouse
model of APAP-induced hepatotoxicity that hypoacetylated
HMBG1 levels are signiﬁcantly elevated in the ﬁrst 3–10 h follow-
ing APAP hepatotoxicity and that this protein provides valuable
information on the histological time course of cell death follow-
ing APAP hepatotoxicity [3]. The hypo and hyperacetylated forms
were determined by mass spectrometry. Following on from this,
Craig et al. found that although levels of HMGB1 were signiﬁ-
cantly higher in patients with acute liver injury, there was no sig-
niﬁcant difference between patients whose liver injury was APAP12 vol. 56 j 1003–1005
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Fig. 1. Potential biomarkers in APAP-induced acute liver injury and therapeutic targets. NAPQI is a toxic metabolite produced in APAP overdose which causes
hepatocyte cell death predominantly by necrosis. The necrotic hepatocytes release HMGB1 and full length keratin-18. Cells that die by apoptosis release caspase-cleaved
keratin-18. HMGB1 (probably in conjunction with lipopolysaccharide) further ampliﬁes the initial insult by initiating a secondary inﬂammatory response and increasing the
severity of tissue injury.
Editorialor non-APAP-induced. In addition, levels of HMGB1 failed to pre-
dict survival [5].
The study by Antoine et al. [2] adds to the existing data and
clariﬁes some of the apparently discordant results. Eighty-four
patients who presented following APAP overdose were catego-
rised into those with normal and abnormal liver function tests
(LFTs). The study showed that all the biomarkers (total HMGB1,
acetylated HMGB1, cK18, and full-length FL-K18) were signiﬁ-
cantly elevated in the sera of patients with APAP overdose asso-
ciated with abnormal LFTs compared to controls. Importantly,
there was no signiﬁcant elevation of these biomarkers in patients
with APAP overdose who had normal LFTs suggesting that these
biomarkers are sensitive at identifying patients who actually
have APAP-induced acute liver injury. As serial analysis of the
sera was also carried out, the results showed that necrosis was1004 Journal of Hepatology 2012the predominant form of cell death in the acute phase following
APAP overdose as levels of total HMGB1 and FL-K18 were more
elevated in the acute phase compared to the markers of apoptosis
as has been observed previously [11,12]. Acetylated HMGB1 was
elevated in the later stages of APAP overdose in patients who died
or required liver transplantation. As the acetylated form of
HMGB1 is thought to be derived from activated immune cells,
this conﬁrms the ﬁndings from other studies which have shown
that activation of the innate immune system occurs as a second-
ary phenomenon following hepatocyte death which may amplify
the inﬂammatory response [13,14]. Samuel et al. have previously
suggested that an ideal predictive factor for determining progno-
sis in ALF should be more applicable at predicting death rather
than survival. For this reason, the result observed with acetylated
HMGB1 is of immense interest [15]. The performance of serialvol. 56 j 1003–1005
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analysis is commendable as it provides detailed information on
the cellular events following APAP-induced liver injury and in
so doing, allows for the development of potential targeted thera-
peutic agents. Fig. 1 illustrates the mechanism by which the var-
ious markers of cell death are generated and potential
therapeutic targets.
The biomarkers of necrosis (HMGB1 and FL-K18) were both
shown to have a strong and signiﬁcant correlation with pro-
thrombin time, a marker of synthetic liver dysfunction, and ALT
activity which is a marker of hepatocellular injury. The mean
serum level of all the biomarkers was signiﬁcantly higher in the
patients that fulﬁlled the KCC poor prognostic criteria compared
to patients that did not. The biomarkers of necrosis were more
accurate at the prediction of patients with a poor prognosis. Acet-
ylated HMGB1 was ‘‘excellent’’ at predicting which patients met
the KCC with an AUC of 0.93 and ‘‘good’’ at predicting which
patients were likely to die or require organ transplantation with
an AUC of 0.87.
They reported on ‘apoptotic index’ which is a ratio of cK18 as a
proportion of overall K18, which was signiﬁcantly lower in
patients who fulﬁlled the KCC. It is not clear what this represents
and without simultaneous liver biopsy correlation, it remains
speculative. Intriguingly, the observation that spontaneous sur-
vival following acute liver injury was associated with increased
levels of caspase activation is counter-intuitive but has also been
made by Volkmann et al. [6]. The mechanism through which the
increased caspase activation may increase survival is through
increased levels of proregenerative cytokines such as IL-6 and
TNF-a [6]. The authors did not measure the circulating cytokines
and this hypothesis will need to be conﬁrmed in future studies.
The impact of the results generated from this study would be
further strengthened by making available the raw data from the
M30 (cleaved) and M65 (total) ELISAs, which were used in deriv-
ing the results of the full length K18 levels which served as a sur-
rogate marker for necrosis. It would have also been useful to seek
histological conﬁrmation on the degree of apoptosis and necrosis
from the livers of patients who died or required a liver transplant.
Of note, an inter- and intra-assay variability of less than 20% was
quoted. For these biomarkers to be useful in clinical practice, one
would expect a coefﬁcient of variation which is much less than
this.
One of the methods used for HMGB1 determination was the
previously mentioned ELISA. Whilst this is a readily available
and convenient way to quantify HMGB1 in serum, there is some
evidence in the literature that this assay may fail to accurately
quantify HMGB1 as various molecules present in the serum
may complex with HMGB1 and therefore interfere with its detec-
tion by the ELISA technique [16,17]. More studies are therefore
needed to investigate methods by which this technique can be
improved prior to it being considered for use in the clinical set-
ting. The accurate detection of HMGB1 is particularly important
in liver disease. Takano et al. have shown that the plasma levels
of HMGB1 are elevated in ALF. In addition, their results suggest
that HMGB1 neutralising antibodies may have a protective effect
against acute liver injury [18]. The growing number of HMGB1
inhibitors in development strengthens the need for a reliable
diagnostic tool.
The exciting and novel results from this study pave the way
and further highlight the need for additional equally wellJournal of Hepatology 2012conducted studies to be carried out so as to ascertain whether
biomarkers of cell death in patients with acute liver injury may
be of prognostic value and whether they can be used to guide
novel approaches to therapy.Conﬂict of interest
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